Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Nieves Martinez Lago


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


N. Martinez Lago1, M. Carmona Campos2, P. Gonzalez Villarroel3, M. Salgado Fernandez4, J. De la Camara Gomez5, C. Romero Reinoso6, A. Cousillas Castiñeiras7, Y. Vidal Insua8, J.C. Mendez Mendez9, C. Reboredo Rendo1, M. Covela Rua2, G. Quintero Aldana2, B. Graña Suarez1, A. Carral Maseda2, M. Jorge Fernandez3, M.L. Pellon Augusto5, C. Grande Ventura3, M.E. Gallardo Martin7, A. Fernández Montes10, M. Reboredo Lopez1

Author affiliations

  • 1 Medical Oncology, CHUAC - Complexo Hospitalario Universitario A Coruña, 15006 - A Coruña/ES
  • 2 Medical Oncology, Hospital Universitario Lucus Augusti, Lugo/ES
  • 3 Medical Oncology, Hospital Universitario Alvaro Cunqueiro, Vigo/ES
  • 4 Medical Oncology, Complejo Hospitalario De Ourense, Ourense/ES
  • 5 Medical Oncology, Complexo Hospitalario Universitario de Ferrol, Ferrol/ES
  • 6 Medical Oncology, POVISA, Vigo/ES
  • 7 Medical Oncology, Complexo Hospitalario Universitario de Pontevedra, Pontevedra/ES
  • 8 Medical Oncology, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela/ES
  • 9 Medical Oncology, Centro Oncologico de Galicia, A Coruña/ES
  • 10 Medical Oncology, Complexo Hospitalario Universitario de Ourense, 32005 - Orense/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3139


Aflibercept (Af) significantly improves progression-free (PFS) and overall survival (OS) when added to FOLFIRI, in the overall population of patients (pts) pretreated with oxaliplatin-based therapy. A subset analysis of pts (>65years) included in the VELOUR trial, suggests a consistent benefit in OS in PFS, but increased grade 3-4 toxicity. Our hypothesis was that selected pts >70y with good PS could benefit from FA, provided they underwent a careful monitoring of toxicity.


Retrospective, multicenter, observational study of mCRC pts >70 years (y) treated with FA as part of routine clinical practice at 8 hospitals from the Galician Research Group on Digestive Tumours (GITuD).


From 338 patients treated with FA between June 2013 to November 2018, 75 pts were recorded. Median age was 72.7 y (range 70-84 y), and 33.4% were >75y. 65.3% were male, 87.5% ECOG PS0-1, 42.5 % left-sided location, 76.0 % low grade, 59.5% RASmt and 77.3 % primary tumor resection. Prior therapy included bevacizumab (56%) and anti-EGFR agents (24%), only adjuvant treatment (5.3%). Median of FA cycles was 10 (range 1-35 cycles). Overall Response Rate (ORR) and disease control rate (DCR) were 30.7% and 65.4%, respectively. With a median follow-up of 27.1 months (m), median PFS was 6.6 m (95% CI, 5.3-7.9 m) and median OS was 15.1 m (95% CI, 12.5-17.8 m). The most common grade 3-4 toxicities overall were asthenia (21.3%), neutropenia (14.7%) and diarrhoea (14.7%). Af-related toxicities were hypertension (5.3%), dysphonia (5.3%) and proteinuria (2.7%). Two patients experienced grade 5 toxicity.This toxicity was managed with dose reduction of Af in 34.7% of cases, dose reduction of FOLFIRI on 56.0% and discontinuation of Af in 18.6%.


Older patients with mCRC are underrepresented in clinical trials. The VELOUR study included only 6.4% pts >75y of age and only 14% included in the substudy of patients >65y were >75y. Patients >65y treated with FA in the VELOUR trial experienced a high rate of G3-4 adverse events (89.3%). Our series confirms that with careful pt selection and dose adjustment based on toxicity, patients >70y can be treated with FA with a 52.0% of grade 3-4 toxicity, results that are comparable to those of younger patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Galician Research Group on Digestive Tumours (GITuD).


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.